1.Relationship between TMPRSS2: ERG and the pathological grade of prostate cancer.
Fa-xian YI ; Hong LI ; Qiang WEI ; Xiang LI ; Hao ZENG
National Journal of Andrology 2015;21(10):887-891
OBJECTIVETo study the relationship between TMPRSS2: ERG gene fusion and the pathological grade of prostate cancer (PCa).
METHODSWe collected fresh prostatic tissue samples from 62 patients with PCa and another 10 with benign prostatic hyperplasia ( BPH) and included 9 cancer cell strains as the control. We examined the TMPRSS2:ERG fusion gene in the PCa samples by nest RT-PCR, compared the Gleason scores between the TMPRSS2:ERG-positive and -negative cases, and analyzed the association of TMPRSS2: ERG fusion with the pathological features of PCa.
RESULTSThe TMPRSS2: ERG fusion gene was detected in 28 (45.16%) of the PCa cases, but in none of the 10 BPH cases or the 9 cancer cell strains. No statistically significant differences were found in the Gleason scores between the TMPRSS2:ERG-positive and -negative cases (Z = -0.609, P = 0.542), but the primary Gleason score was markedly higher in the former than in the latter (Z = -2.600, P = 0.009). Univariate logistic regression analysis showed that TMPRSS2:ERG was associated with the cribriform growth pattern (OR = 6.250, P = 0.002), foamy gland morphology (OR = 6.666, P = 0.023), and signet-ring cells (OR = 3.240, P = 0.035), but multivariate logistic regression analysis manifested that it was associated with the cribriform growth pattern only (OR = 3.750, P = 0.033).
CONCLUSIONTMPRSS2:ERG gene fusion was associated with higher pathological grades of prostate cancer.
Gene Fusion ; Humans ; Male ; Oncogene Proteins, Fusion ; genetics ; Prostatic Hyperplasia ; genetics ; Prostatic Neoplasms ; genetics ; pathology
2.The regulatory pathways leading to stem-like cells underlie prostate cancer progression.
Chun-Jung LIN ; U-Ging LO ; Jer-Tsong HSIEH
Asian Journal of Andrology 2019;21(3):233-240
Prostate cancer (PCa) is the most common cause of malignancy in males and the third leading cause of cancer mortality in the United States. The standard care for primary PCa with local invasive disease mainly is surgery and radiation. For patients with distant metastases, androgen deprivation therapy (ADT) is a gold standard. Regardless of a favorable outcome of ADT, patients inevitably relapse to an end-stage castration-resistant prostate cancer (CRPC) leading to mortality. Therefore, revealing the mechanism and identifying cellular components driving aggressive PCa is critical for prognosis and therapeutic intervention. Cancer stem cell (CSC) phenotypes characterized as poor differentiation, cancer initiation with self-renewal capabilities, and therapeutic resistance are proposed to contribute to the onset of CRPC. In this review, we discuss the role of CSC in CRPC with the evidence of CSC phenotypes and the possible underlying mechanisms.
Androgen Antagonists/therapeutic use*
;
Cell Differentiation/genetics*
;
Disease Progression
;
Humans
;
Male
;
Neoplastic Stem Cells/pathology*
;
Prostatic Neoplasms/pathology*
;
Prostatic Neoplasms, Castration-Resistant/pathology*
;
Signal Transduction/genetics*
3.Androgen receptor mutation and progression of prostate cancer.
Jian-Guo MA ; Wen-Ping LI ; Yu-Qing JIANG
National Journal of Andrology 2011;17(7):649-654
Prostate cancer growth is almost wholly dependent on the route of the androgen receptor and most therapies aimed at blocking this signaling axis are useful tools in the management of this disease. Unfortunately such therapies invariably fail, and the cancer progresses to an androgen-independent stage. In such cases, androgen receptor mutation almost always occurs and much evidence suggests the continuous growth of the tumor. One mechanism by which the receptor is thought to remain active is mutation. This paper reviews the molecular mechanism of tumor growing after androgen receptor mutation and some of the promising management principles and systemic chemotherapy options against prostate cancer.
Disease Progression
;
Humans
;
Male
;
Mutation
;
Prostatic Neoplasms
;
genetics
;
pathology
;
Receptors, Androgen
;
genetics
4.Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer.
Hanqing ZENG ; Yajun XIAO ; Gongchen LU ; Yong CHEN
Journal of Huazhong University of Science and Technology (Medical Sciences) 2003;23(4):373-379
To study the expression of matrix metalloproteinase-2 and -9 in human prostate cancer, matrix metalloproteinase-2 and -9 were immunohistochemically detected in tissues of prostate cancer and benign prostatic hyperplasia (BPH). Our results showed that matrix metalloproteinase-2 and -9 levels in prostate cancer were much higher than those in tissues of BPH, with the cancer invasion being positively correlated with the expression of the metalloproteinases. It is concluded that matrix metalloproteinase-2 and -9 are better molecular markers, which are of help in the diagnosis and prediction of prognosis of prostate cancer.
Humans
;
Immunohistochemistry
;
Male
;
Matrix Metalloproteinase 2
;
biosynthesis
;
genetics
;
Matrix Metalloproteinase 9
;
biosynthesis
;
genetics
;
Neoplasm Invasiveness
;
Prostatic Hyperplasia
;
metabolism
;
pathology
;
Prostatic Neoplasms
;
metabolism
;
pathology
5.Detection and significance of fusion gene between TMPRSS2 and ETS transcription factor genes in fresh prostatic cancer tissues in Chinese patients.
Hua XIANG ; Zong-xin LING ; Ke SUN ; Guo-ping REN ; Qi-han YOU ; Xiong-zeng ZHU
Chinese Journal of Pathology 2011;40(3):187-188
Carcinoma
;
genetics
;
metabolism
;
pathology
;
surgery
;
China
;
Humans
;
Male
;
Oncogene Proteins, Fusion
;
genetics
;
Prostatic Hyperplasia
;
genetics
;
metabolism
;
pathology
;
surgery
;
Prostatic Neoplasms
;
genetics
;
metabolism
;
pathology
;
surgery
;
Proto-Oncogene Proteins c-ets
;
genetics
;
metabolism
;
Reverse Transcriptase Polymerase Chain Reaction
;
Serine Endopeptidases
;
genetics
;
metabolism
6.Progress in the studies of prostate cancer related molecules.
Wei SHI ; Li DONG ; Jun-sheng BAO
National Journal of Andrology 2015;21(4):357-362
Prostate cancer is one of the common malignant tumors of the urinary system and mostly found in elderly men. Like most tumors, prostate cancer involves a variety of molecules in its occurrence and progression. More studies on the development of prostate cancer focus on the tumor markers, DNA damage repair related genes, and tumor invasion and metastasis related factors. This article presents an overview on the research progress in these three aspects.
Biomarkers, Tumor
;
Biomedical Research
;
DNA Repair
;
Disease Progression
;
Humans
;
Male
;
Neoplasm Invasiveness
;
Prostatic Neoplasms
;
genetics
;
pathology
7.Expression of human membrane associated sialidase gene in prostate carcinoma PC-3 cell line.
Chinese Journal of Applied Physiology 2005;21(3):299-304
Cell Line, Tumor
;
Genetic Vectors
;
Humans
;
Male
;
Neuraminidase
;
genetics
;
metabolism
;
Prostate
;
metabolism
;
Prostatic Neoplasms
;
metabolism
;
pathology
8.Clinical significance of six-transmembrane epithelial antigen of the prostate expressed in prostatic carcinoma.
Liaoyuan LI ; Jiefang LI ; Zhoujun SHEN ; Weijun LIU ; Zhaodian CHEN
National Journal of Andrology 2004;10(5):351-354
OBJECTIVETo investigate the relationship between six-transmembrane epithelial antigen of the prostate (STEAP) expression and the histologic grading of prostatic carcinoma (PCa).
METHODSDifferent prostatic tissues and non-prostatic tumors, 131 cases of PCa, 164 cases of benign prostate hyperplasia (BPH), and 56 cases of non-prostatic malignancies, were analyzed for the expression of STEAP by using STEAP monoclonal antibody and SP immunohistochemical staining. The positive area unit (PU) was introduced to describe the intensity of STEAP expression.
RESULTSThe prostatic tissues of all but 3 cases of PCa and 5 cases of BPH were stained positively, while all of the non-prostatic tumors were stained negatively. There was a significant negative correlation between the STEAP expression and the histologic grading of PCa.
CONCLUSIONSTEAP can be a prognostic marker of PCa and a potential therapeutic target in PCa.
Antigens, Neoplasm ; analysis ; genetics ; Humans ; Immunohistochemistry ; Male ; Oxidoreductases ; Prostatic Neoplasms ; diagnosis ; immunology ; pathology
9.Screening of differently expressed genes in human prostate cancer cell lines with different metastasis potentials.
Anping, SONG ; Guoning, LIAO ; Mingfu, WU ; Yunping, LU ; Ding, MA
Journal of Huazhong University of Science and Technology (Medical Sciences) 2007;27(5):582-5
In order to screen the genes differentially expressed in two human prostate cancer cells with different metastasis potentials, suppression subtractive hybridization (SSH) was done twice on human prostate cancer cell line with high potential of metastasis PC3M-1E8 and its synogenetic cell line PC3M-2B4 with low metastasis potential. In the first subtraction PC3M-2B4 was used as tester and PC3M-1E8 as driver and the forward subtractive library was constructed. In the second on the tester and driver were interchanged and the reverse subtractive library was constructed. The screened clones of both libraries were sequenced and Gene Bank homology search was performed. Some clones were confirmed by quantitative real-time PCR. The results showed that two subtractive libraries containing 238 positive clones were constructed. Analysis of 16 sequenced clones randomly picked from two libraries showed that 4 differentially expressed gene fragments were identified as new EST with unknown functions. It was concluded that two subtractive libraries of human prostate cancer cell lines with different metastasis potentials were constructed successfully.
Cell Line, Tumor
;
Gene Expression Profiling
;
Gene Expression Regulation, Neoplastic
;
Gene Library
;
Neoplasm Metastasis/*genetics
;
Nucleic Acid Hybridization/*methods
;
Prostatic Neoplasms/*genetics
;
Prostatic Neoplasms/pathology
10.MiR-124 suppresses the proliferation of human prostate cancer PC3 cells by targeting PKM2.
Lei LÜ ; Jing-Dong YUAN ; Zuo-Liang CAO ; Tao HUANG ; Chuan-Hua ZHANG ; Liang WANG ; Fu-Qing ZENG
National Journal of Andrology 2014;20(6):495-499
OBJECTIVETo explore the mechanism of miR-124 inhibiting the proliferative activity of prostate cancer PC3 cells.
METHODSLuciferase reporter gene assay was used to examine the specific binding ability of miR-124 to PKM2 mRNA 3'-UTR. After miR-124 was transfected mimic to PC3 cells, the expression levels of PKM2 mRNA and protein were detected by real-time fluorescence quantitative PCR (qRT-PCR) and Western blot, respectively. The effects of miR-124 mimic and PKM2 siRNA on the proliferative activity of the PC3 cells were determined by MTT assay.
RESULTSThe expressions of PKM2 mRNA and protein were upregulated (5.12 +/- 0.35) times and (4.05 +/- 0.20) times respectively in the PC3 cells as compared with those in the RWPE-1 cells (P < 0.05). Luciferase reporter gene assay demonstrated that miR-124 targeted PKM2 3'-UTR. At 24 hours after transfection with miR-124 mimic, the PKM2 protein expression in the PC3 cells was downregulated (0.16 +/- 0.04) times (P < 0.05), while the PKM2 mRNA level was not changed significantly (P > 0.05), as compared with the control group. MTT assay showed that both miRNA-124 mimic and PKM2 siRNA could inhibit the proliferation of the PC3 cells, but the former exhibited a greater inhibitory effect than the latter. After transfection with miR-124 mimic and PKM2 siRNA, the cell growth rates were (66.20 +/- 5.10)% vs (82.10 +/- 6.35)% at 24 hours (P < 0.05) and (49.34 +/- 2.37)% vs (70.10 +/- 5.80)% at 48 hours (P < 0.05).
CONCLUSIONmiR-124 can suppress the proliferation of PC3 cells by regulating the PKM2 gene.
Carrier Proteins ; genetics ; metabolism ; Cell Line, Tumor ; Cell Proliferation ; genetics ; Humans ; Male ; Membrane Proteins ; genetics ; metabolism ; MicroRNAs ; genetics ; Prostatic Neoplasms ; genetics ; metabolism ; pathology ; Thyroid Hormones ; genetics ; metabolism ; Transfection